This is a list of all the questions and their associated study carrel identifiers. One can learn a lot of the "aboutness" of a text simply by reading the questions.
| identifier | question |
|---|---|
| cord-009263-w8bmmgtj | A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors Unexpected structure for the N- terminal domain of hepatitis C virus envelope glycoprotein E1 A novel membrane fusion protein family in Flaviviridae? |
| cord-006856-b1w25ob5 | P21 FTY720 interferes with effector functions and downregulates protein expression of S1P1 and S1P4 in human dendritic cells tures with FTY720/ FTY720-P- treated DC illustrated a cytokine production profile with a lower IFN-?( 22% vs. 25% relative reduction) and a higher IL-4( 64% vs. 92% relative increase), indicating a shift from Th1 toward Th2 differentiation as previously evinced for S1P. DC yields, phenotypic differentiation into iDC and mDC( besides a minor reduction in CD18 surface expression), as well as the investigated mechanisms of iDC antigen uptake( bacterial phagocytosis, mannose receptor- mediated, and fluid- phase endocytosis), were not affected at therapeutically relevant concentrations. |
| cord-002410-2zi5iv2t | The family of IL-10-related cytokines and their receptors: related, but to what extent? |
| cord-018785-tcr5xlf8 | Should we treat asymptomatic bacteriuria after renal transplantation? |
| cord-016343-wc3i54fc | ( 2005)? |
| cord-253825-d9borky8 | a broad- spectrum antiviral compound that blocks viral fusion Arbidol: a broad- spectrum antiviral that inhibits acute and chronic HCV infection Similar uptake but different trafficking and escape routes of reovirus virions and ISVPs imaged in polarized MDCK cells Design of inhibitors of influenza virus membrane fusion: synthesis, structure- activity relationship and in vitro antiviral activity of a novel indole series Antiviral activity of arbidol, a broad- spectrum drug for use against respiratory viruses, varies according to test conditions Antiviral chemotherapeutic agents against respiratory viruses: where are we now and what's in the pipeline? |
| cord-001834-6xf4o3oy | : What can we look forward to? |
| cord-284904-qw1ig2v4 | Chloroquine is a potent inhibitor of SARS coronavirus infection and spread Anti- HIV effects of chloroquine: mechanisms of inhibition and spectrum of activity Effects of chloroquine on viral infections: an old drug against today's diseases? |
| cord-015941-4fz79wzf | Comparison of a commercial IgM capture ELISA with dengue antigen focus reduction microneutralization test and the centers for disease control dengue IgM capture- ELISA PCR detection of nearly any dengue virus strain using a highly sensitive primer cocktail Do babesiosis and malaria share a common disease process? |
| cord-013176-6ckuya1w | : Is There Sufficient Evidence to Define a Health- Promoting Polyphenol- Rich Dietary Pattern? |
| cord-000830-jiy4cp4n | Diagnostic molecular microbiology review Rapid enterovirus molecular testing in cerebrospinal fluid reduces length of hospitalization and duration of antibiotic therapy in children with aseptic meningitis Nucleic acid amplification and related techniques in microbiological diagnosis and epidemiology Molecular detection and quantitative analysis of the entire spectrum of human adenoviruses by a two- reaction real- time PCR assay Typing of human adenoviruses in specimens from immunosupressed patients by PCR- fragment length analysis and real- time quantitative PCR Monitoring of cytomegalovirus reactivation in bone marrow tranplant recipients by real- time PCR Comparison of commercial and in- house real- time PCR assays for quantification of Epstein- Barr virus( EBV) DNA in plasma Cytomegalovirus quantification: where to next in optimising patient management? |
| cord-001421-6t5puo6p | The nomenclature of chronic hepatitis: time for a change Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI- TOF MS in malignant bile duct stricture Evaluation of liver fibrosis: a concise review Biopsy and non- invasive methods for the diagnosis of liver fibrosis: does it take two to tango? |
| cord-276364-zyw5aukk | deranges dengue virion maturation Knockdown of autophagy enhances the innate immune response in hepatitis C virus- infected hepatocytes Activation of the unfolded protein response and autophagy after hepatitis C virus infection suppresses innate antiviral immunity in vitro Cholesterol manipulation by West Nile virus perturbs the cellular immune response Perturbation of intracellular cholesterol and fatty acid homeostasis during flavivirus infections Autophagy in cell death: an innocent convict? |
| cord-260099-mthwab4p | The binding effects of NIH3T3-LSECtin cells to HCV virions could be blocked by either soluble LSECtin or EGTA, indicating the binding specificity and the Ca 2? |
| cord-000008-3dgjv0x1 | The liver as a site of T- cell apoptosis: graveyard, or killing field? |
| cord-017948-fqhl1qb4 | Emerging infectious disease agents and their potential threat to transfusion safety Detection of prion infection in variant Creutzfeldt- Jakob disease: a blood- based assay Threat of dengue to blood safety in dengue- endemic countries PCR detection of nearly any dengue virus strain using a highly sensitive primer cocktail Do babesiosis and malaria share a common disease process? |
| cord-256769-flfycl7i | divergent role of CD46 cytoplasmic domains in T cell induced inflammation Complement and coagulation: strangers or partners in crime? |
| cord-000638-ss1435el | Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation? |
| cord-261287-l4649du3 | a randomised controlled trial of pegylatedinterferona-2b plus ribavirin vs interferona-2b plus ribavirin as primary treatment of chronic hepatitis C in HIV co- infected patients Is an'À la Carte'combination Interferon Alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? |
| cord-281389-sht0yx4a | Why would the host dampen its immune response to infection? |
| cord-018220-8m11ig06 | Two outbreaks of severe respiratory disease in nursing homes associated with rhinovirus Human coronaviruses: what do they cause? |
| cord-280330-ibvbowl0 | The search for new therapies for human cytomegalovirus infections Measles control- can measles virus inhibitors make a difference? |
| cord-299747-qovrstak | What are the main challenges to designing and optimizing new inhibitors of non- HCV positive- strand RNA viruses? |
| cord-284551-j0nooxmd | Hepatitis C virus subgenomic replicons induce endoplasmic reticulum stress activating an intracellular signaling pathway The role of the unfolded protein response in tumour development: friend or foe? |
| cord-017506-t86v3zw3 | How harmful is hazardous alcohol use and abuse in HIV infection: do health care providers know who is at risk? |
| cord-017506-t86v3zw3 | In fl uence of chronic alcohol abuse on body weight and energy metabolism: is excess ethanol consumption a risk factor for obesity or malnutrition? |
| cord-293790-7hyelm88 | Given the involvement of autophagy at the site of replication of other positive- stranded RNA viruses, are the autophagy proteins or structure involved in HCV replication? |
| cord-026112-58sa5z03 | Antiretroviral drug resistance mutations in naïve Islamic Republic of Iran AIDS Progress Report HIV-1 genetic diversity and transmitted drug resistance frequency among Iranian treatment- naive, sexually infected individuals Epidemiological distribution and genotype characterization of the hepatitis C virus among HIV patients in Kashan High prevalence of HCV coinfection in HIV- infected individuals in Shiraz, Islamic Republic of Iran Sexually transmitted hepatitis C infection: the new epidemic in MSM? |
| cord-286719-1xjmlwqr | Cytomegalovirus: pathogen, paradigm, and puzzle International consensus guidelines on the management of cytomegalovirus in solid organ transplantation Neonatal cytomegalovirus blood load and risk of sequelae in symptomatic and asymptomatic congenitally infected newborns Is HCMV a tumor promoter? |
| cord-299719-bvdsz626 | key: cord-299719-bvdsz626 authors: Fournier, C.; Duverlie, G.; Castelain, S. title: Are trans‐complementation systems suitable for hepatitis C virus life cycle studies? |
| cord-293857-o8rlqsq5 | : pharmacokinetic and pharmacodynamic interactions between AEDs Discontinuation of phenytoin and carbamazepine in patients receiving felbamate Effects of felbamate on the pharmacokinetics of phenobarbital Efavirenzstill first- line king? |
| cord-303189-ktl4jw8v | The interferon response to intracellular DNA: why so many receptors? |
| cord-273555-i1d4quos | Letter: does the IFNL4 gene discovery really provide a causal role for the IL28B haplotype blocks? |
| cord-273555-i1d4quos | Letter: does the IFNL4 gene discovery really provide a causal role for the IL28B haplotype blocks? |
| cord-293646-d4qcckh1 | The bicyclic lactam 22 is a mechanismbased inhibitor of HCV NS3 whilst additional examples of bis- benzimidazole derivatives that rely upon Zr?' |
| cord-006129-5rog0s98 | Are viral- encoded microRNAs mediating latent HIV-1 infection? |
| cord-006129-5rog0s98 | Current perspectives in microRNAs( miRNA) Host- virus interaction: a new role for microRNAs Silencing viral microRNA as a novel antiviral therapy? |
| cord-307817-2vy28i4m | Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity Structure- activity relationship studies on clinically relevant HIV-1 NNRTIs Non- nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections Next- generation integrase inhibitors: where to after raltegravir? |
| cord-015372-76xvzvdg | Can any of the cognitive assessments help to predict behavioural dysfunction.'? |
| cord-015372-76xvzvdg | This is the first Irish Report of PSP and a most remarkable use of saxitoxin(?) |
| cord-280878-1kt51viz | A new structural label for infrared spectroscopy Conductance and amantadine binding of a pore formed by a lysine- flanked transmembrane domain of SARS coronavirus envelope protein Model of a putative pore: The pentameric α- helical bundle of SARS coronavirus E protein in lipid bilayers Protein- protein interactions of viroporins in coronaviruses and paramyxoviruses: New targets for antivirals? |
| cord-280878-1kt51viz | The SARS coronavirus E protein interacts with PALS1 and alters tight junction formation and epithelial morphogenesis Functional role of human immunodeficiency virus type 1 vpu Detection of drug- induced conformational change of a transmembrane protein in lipid bilayers using site- directed spin labeling Do viral proteins possess unique biophysical features? |
| cord-305263-fgwf6wy3 | alpha-2a with or without ribavirin for HBeAg- negative chronic hepatitis B Increasing proportion of herpes simplex virus type I as a cause of genital herpes infection in college students Herpes simplex virus encephalitis: new infection or reactivation? |
| cord-305303-82n96ukr | Bacterial toxin- antitoxin systems: more than selfish entities? |
| cord-011182-nbtfb39r | The hepatitis C virus persistence: how to evade the immune system? |
| cord-011182-nbtfb39r | The importance of intrinsic disorder for protein phosphorylation HCV infection and NS-3 serine protease inhibitors Analysis of hepatitis C virus RNA dimerization and core- RNA interactions Virus escape CTL or B cell epitopes? |
| cord-307934-84zfabti | Trojan exosomes riding the Trojan horse? |
| cord-289321-ahl46ql9 | In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms Complete replication of hepatitis C virus in cell culture Novel therapies for hepatitis C-one pill fits all? |
| cord-289321-ahl46ql9 | What does cis- dominant resistance mean mechanistically? |
| cord-341071-nwrl1qws | Are Aptamers the Wished Antiviral Drugs? |
| cord-332747-u46xryoo | Case Closed? |
| cord-274080-884x48on | Molecular mechanism of divalentmetal- induced activation of NS3 helicase and insights into Zika virus inhibitor design HCV infection by cell- to- cell transmission: choice or necessity? |
| cord-274080-884x48on | Novel ESCRT functions in cell biology: spiraling out of control? |
| cord-321053-lgae22f8 | Novel therapies for hepatitis C-one pill fits all? |
| cord-333331-ddcz7zck | Due to cutting in the region between B1 and B2, NheI- digestion bands were observed at approximately 250- 454( 225? 229) bp in the Pre- LAMP product, in contrast to 220- 400 bp in the AP- LAMP and AP- B3 LAMP products. |
| cord-321230-b5a1z14w | The impact of HCV SVR from direct acting antiviral and interferon- based treatments on mortality in a large population based cohort study Changes in synthetic opioid involvement in drug overdose deaths in the United States Known fentanyl use among clients of harm reduction sites in British Columbia What is killing people with hepatitis C virus infection? |
| cord-255781-55zrmgxq | Cytoskeleton rearrangement induced by tetraspanin engagement modulates the activation of T and NK cells Natural killer cells: primary target for hepatitis C virus immune evasion strategies? |
| cord-255781-55zrmgxq | Genital HPV infection- fact sheet Epidemiologic classification of human papillomavirus types associated with cervical cancer Update on human papillomavirus vaccines: life saver or controversy magnet? |
| cord-255781-55zrmgxq | Interferon- alpha- induced trail on natural killer cells is associated with control of hepatitis C virus infection Impaired effector function of hepatitis C virus- specific CD81 T cells in chronic hepatitis C virus infection Association of genetic polymorphisms with interferon- induced haematologic adverse effects in chronic hepatitis C patients Reducing the immunogenicity and improving the in vivo activity of trichosanthin by site- directed pegylation Pegylated interferons: what role will they play in the treatment of chronic hepatitis C? |
| cord-284693-mgpxnnk0 | -pre- or post- liver transplantation? |
| cord-284693-mgpxnnk0 | The Oral Ganciclovir International Transplantation Study Group Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir Who among cytomegalovirus- seropositive liver transplant recipients is at risk for cytomegalovirus infection? |
| cord-284693-mgpxnnk0 | current German practice Use of Everolimus- based Immunosuppression to Decrease Cytomegalovirus Infection After Kidney Transplant Antiviral drug resistance of human cytomegalovirus Epstein- Barr virus infections: biology, pathogenesis, and management Lymphoproliferative disorders and de novo malignancies in intestinal and multivisceral recipients Posttransplant lymphoproliferative disease following liver transplantation Occurrence of post- transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection? |
| cord-342676-ykog278j | vitro RNA chaperoning and intrinsic disorder in the core proteins of Flaviviridae Interaction of hepatitis C virus core protein with viral sense RNA and suppression of its translation Selective binding of hepatitis C virus core protein to synthetic oligonucleotides corresponding to the 5′ untranslated region of the viral genome Specific in vitro association between the hepatitis C viral genome and core protein Detection of Cellular Proteins and Viral Core Protein Interacting with the 5′ Untranslated Region of Hepatitis C Virus RNA Role of RNA structures in genome terminal sequences of the hepatitis C virus for replication and assembly Down- regulation of the internal ribosome entry site( IRES)-mediated translation of the hepatitis C virus: critical role of binding of the stem- loop IIId domain of IRES and the viral core protein Hepatitis C virus RNA: molecular switches mediated by long- range RNA- RNA interactions? |
| cord-321773-5fw9abzl | Why, how, when? |
| cord-347992-coby2m6e | In vitro selection procedures for identifying DNA and RNA aptamers targeted to nucleic acids and proteins Berzal- Herranz, A. RNA selection and evolution in vitro: powerful techniques for the analysis and identification of new molecular tools Aptamers: a new class of oligonucleotides in the drug discovery pipeline? |
| cord-345898-a6vt8kso | Flavivirus induces interferon- beta gene expression through a pathway involving RIG- I- dependent IRF-3 and PI3K- dependent NF- kappaB activation A dark- to- bright reporter cell for classical swine fever virus infection Tricistronic hepatitis C virus subgenomic replicon expressing double transgenes Structural analysis of foot- and- mouth disease virus 3C protease: a viable target for antiviral drugs? |
| cord-017764-h1w9gbxk | An Inhibitor of the Mathematical modeling of HCV infection: what can it teach us in the era of direct- acting antiviral agents? |
| cord-017764-h1w9gbxk | How were new medicines discovered? |
| cord-017764-h1w9gbxk | Impact of highthroughput screening on biomedical research Cell- based assays to identify inhibitors of viral disease Anti- infectives: can cellular screening deliver? |
| cord-266738-8xx1xm2d | The paradox of highly effective sofosbuvir- based combination therapy despite slow viral decline: can we still rely on viral kinetics? |
| cord-266738-8xx1xm2d | The paradox of highly effective sofosbuvir- based combination therapy despite slow viral decline: can we still rely on viral kinetics? |
| cord-266738-8xx1xm2d | The paradox of highly effective sofosbuvir- based combination therapy despite slow viral decline: can we still rely on viral kinetics? |
| cord-013244-d6saaiu9 | : a modelling study Hepatitis C in pregnancy in the era of direct- acting antiviral treatment: potential benefits of universal screening and antepartum therapy Considering direct- acting antivirals to cure hepatitis C virus during pregnancy: is this the last treatment frontier? |
| cord-013244-d6saaiu9 | Is Adding HCV screening to the antenatal national screening program in Amsterdam, The Netherlands, Cost- Effective? |
| cord-013244-d6saaiu9 | Should non- Western migrants be screened? |
| cord-013244-d6saaiu9 | The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection Hepatitis C virus treatment: is it possible to cure all hepatitis C virus patients? |
| cord-286334-d9v5xtx7 | Is there within- season waning of influenza type/ subtype vaccine effectiveness with increasing time since vaccination? |
| cord-286334-d9v5xtx7 | What to do next to control the 2019-ncov epidemic? |
| cord-319754-5isw53wl | An Essential"Receptor"or an"Accessory Attachment Factor"for Hepatitis A Virus? PIP5K- driven PtdIns(4,5)P2 synthesis: Regulation and cellular functions Function and dysfunction of the PI system in membrane trafficking PIP2: Choreographer of actin- adaptor proteins in the HIV-1 dance Synchronized HIV assembly by tunable PIP2 changes reveals PIP2 requirement for stable Gag anchoring Quantification of phosphoinositides reveals strong enrichment of PIP2 in HIV-1 compared to producer cell membranes Investigation of the Lipid Binding Properties of the Marburg Virus Matrix Protein VP40 Type I phosphatidylinositol-4-phosphate |
| cord-319754-5isw53wl | Signaling Multifaceted roles for lipids in viral infection Ultrastructure of the replication sites of positive- strand RNA viruses Does form meet function in the coronavirus replicative organelle? |
| cord-312080-pu6m4qad | Why do viruses cause cancer? |
| cord-312080-pu6m4qad | the next future of pharmaco- toxicology and food research? |
| cord-347319-lcuma3eh | Chloroquine is a potent inhibitor of SARS coronavirus infection and spread Effects of chloroquine on viral infections: an old drug against today's diseases? |
| cord-349358-leicos9j | Again, as with other drugs in development against HIV infection, we are confronted with the following major questions: what are the potential side effects from such an approach, and what would be the therapeutic dose window? |
| cord-349358-leicos9j | In other words, what would be the preferred delivery system to use in animals and later on in humans? |
| cord-311823-85wj08gr | Does the converse hold true for a virus such as HCV, which typically establishes a persistent infection characterized by mild( or slowly progressing) disease? |
| cord-311823-85wj08gr | How then can greater benefits be gained from using functional genomics to study virus- host interactions? |
| cord-314567-purplsjn | How Parkinson's disease meets nucleolar stress NF90 isoforms, a new family of cellular proteins involved in viral replication? |
| cord-314567-purplsjn | The nucleolus- a gateway to viral infection? |
| cord-024003-698d15gk | Bacterial components as naturally inspired nano- carriers for drug/ gene delivery and immunization: set the bugs to work? |
| cord-024003-698d15gk | Curcumin inhibits hepatitis B virus infection by down- regulating cccDNA- bound histone acetylation A review on antibacterial, antiviral, and antifungal activity of curcumin Curcumin against hepatitis C virus infection: spicing up antiviral therapies with'nutraceuticals'? |
| cord-024003-698d15gk | Hepatitis C Virus II HCV genotype 4, 5 and 6: distribution of viral subtypes and sustained virologic response rates in clinical trials of approved direct- acting antiviral regimens Defining the possibilities: is short duration treatment of chronic hepatitis C genotype 1 with sofosbuvir- containing regimens likely to be as effective as current regimens? |
| cord-024003-698d15gk | Plant- derived antivirals against hepatitis C virus infection Hepatitis C virus and natural compounds: a new antiviral approach? |
| cord-351365-dc9t3vh3 | Fact or fiction? |
| cord-351365-dc9t3vh3 | What Is a Quasispecies? |
| cord-284376-plwyjhl8 | The paradox of highly effective sofosbuvir- based combination therapy despite slow viral decline: can we still rely on viral kinetics? |
| cord-284376-plwyjhl8 | The paradox of highly effective sofosbuvir- based combination therapy despite slow viral decline: can we still rely on viral kinetics? |
| cord-284376-plwyjhl8 | The paradox of highly effective sofosbuvir- based combination therapy despite slow viral decline: can we still rely on viral kinetics? |
| cord-314254-9ye8tfvz | A strategy to estimate unknown viral diversity in mammals Virology: the virus whose family expanded Bats and viruses: friend or foe? |
| cord-314254-9ye8tfvz | Evolving epidemiology of hepatitis C virus Hepatitis C and liver transplantation Novel therapies for hepatitis C- one pill fits all? |
| cord-324984-ojrpsdt9 | , in patients infected with HIV-1 Chemokine control of West Nile virus infection Virological and immunological response to antiretroviral regimens containing maraviroc in HIV type 1-infected patients in clinical practice: role of different tropism testing results and of concomitant treatments Intensification of a raltegravir- based regimen with maraviroc in early HIV-1 infection Maraviroc and reverse transcriptase inhibitors combinations as potential preexposure prophylaxis candidates( S)-methyl-1-piperazinyl]-4-methylpiperidine( Sch-417690/ Sch- D), a potent, highly selective, and orally bioavailable CCR5 antagonist Pharmacokinetics and short- term safety of 873140, a novel CCR5 antagonist, in healthy adult subjects An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-Fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H- imidazo[4, 5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide( PF-232798) Is PF-232798 a possible successor to maraviroc? |
| cord-324984-ojrpsdt9 | molecular chaperone inhibitors: are we there yet? |
| cord-271635-tydlyc1q | Can methanolic extract of Nigella sativa seed affect glyco- regulatory enzymes in experimental hepatocellular carcinoma? |
| cord-271635-tydlyc1q | Resveratrol down- regulates Myosin light chain kinase, induces apoptosis and inhibits diethylnitrosamine- induced liver tumorigenesis in rats Inflammation and cancer: back to Virchow? |
| cord-271635-tydlyc1q | What do we know so far? |
| cord-271635-tydlyc1q | a potential biomarker of mitochondrial dysfunction? |
| cord-324559-p92y5er2 | The paradox of highly effective sofosbuvir- based combination therapy despite slow viral decline: can we still rely on viral kinetics? |
| cord-324559-p92y5er2 | The paradox of highly effective sofosbuvir- based combination therapy despite slow viral decline: can we still rely on viral kinetics? |
| cord-324559-p92y5er2 | The paradox of highly effective sofosbuvir- based combination therapy despite slow viral decline: can we still rely on viral kinetics? |
| cord-285505-8norumv6 | : What opportunity exists for a better nucleoside/ nucleotide to treat hepatitis C? |
| cord-285505-8norumv6 | In contrast, there was far less protection in clinical trials-why? |
| cord-285505-8norumv6 | Is it possible that raltegravir is inducing a single round of HIV replication, to give an increase in HIV circles? |
| cord-285505-8norumv6 | What is the role of T- cell responses? |
| cord-343963-99rd3o79 | Hepatitis C Virus induces the mitochondrial translocation of Parkin and subsequent mitophagy Autophagy and RNA virus interactomes reveal IRGM as a common target MicroRNAs and immunity: novel players in the regulation of normal immune function and inflammation How do microRNAs regulate gene expression? |
| cord-343963-99rd3o79 | NS5A nonstructural protein: a new paradigm for phosphorylation- dependent viral RNA replication? |
| cord-342901-ca2xxkb2 | So what are we to make of all the proposed ITAFs for PV and other closely related enteroviruses? |
| cord-342901-ca2xxkb2 | virus( HAV) proteinase 3C inhibits HAV IRES- dependent translation and cleaves the polypyrimidine tract- binding protein Polypyrimidine tract binding protein functions as a negative regulator of feline calicivirus translation Stress granules and cell signaling: more than just a passing phase? |
| cord-269194-b1wlr3t7 | Are treatment options available? |
| cord-269194-b1wlr3t7 | For how long will the patient need to be on therapy? |
| cord-269194-b1wlr3t7 | Simple amplification- based assay: A nucleic acid- based point- of- care platform for HIV-1 testing HIV-1 viral load blips are of limited clinical significance HIV cure and eradication: How will we get from the laboratory to effective clinical trials? |
| cord-269194-b1wlr3t7 | Transducers Quantitation of mRNA by the polymerase chain reaction Prehistoric eye disease( trachoma?) |
| cord-269194-b1wlr3t7 | What treatment regimen should be prescribed? |
| cord-330110-pamxy4av | ( TIF) Identification of hepatoprotective flavonolignans from silymarin Multiple effects of silymarin on the hepatitis C virus lifecycle Silibinin and related compounds are direct inhibitors of hepatitis C virus RNAdependent RNA polymerase Synthesis and in vitro anti- hepatitis B virus activities of some ethyl 6-bromo-5-hydroxy-1H- indole-3-carboxylates Antiviral chemotherapeutic agents against respiratory viruses: where are we now and what's in the pipeline? |
| cord-330110-pamxy4av | Interfacial tryptophan residues: a role for the cation- pi effect? |
| cord-023033-tgt69ir6 | Following exposure to the T cell expander, the level of CD4+CD25+ T cells increased 4.5 times( 28.6 2 30.8) in normal controls, but only 1.85 times in AM-2 patients( 6.62? |
| cord-023033-tgt69ir6 | Full- length HCV cDNA corresponding to the pH77 strain previously shown to be infectious in the presence of? |
| cord-023033-tgt69ir6 | Ischemic preconditioning decreased serum ALT activity compared to control( 168? |
| cord-023033-tgt69ir6 | SEMI vs 333? |
| cord-023033-tgt69ir6 | p= O.O2), a difference present both at diagnosis( 2.24? 0.56, p<0.005) and during remission( 4.25 2 0.35, p= O.Ol). |
| cord-027860-s97hdhh6 | ( Do I have cold sores? |
| cord-027860-s97hdhh6 | Do I have genital herpes? |
| cord-027860-s97hdhh6 | How should this change the way I live my life?). |
| cord-027860-s97hdhh6 | The lesions are most Who to Screen? |
| cord-027860-s97hdhh6 | The question,"Do you regularly use condoms?"has little relevance to infection control for many sexual practices. |
| cord-347710-ff64y6ef | : where do we stand? |
| cord-347710-ff64y6ef | Hsp90 inhibitors: a potential treatment for latent EBV infection? |
| cord-347710-ff64y6ef | The hepatitis E virus open reading frame 3 product interacts with microtubules and interferes with their dynamics The ins and outs of tubulin acetylation: more than just a post- translational modification? |
| cord-347710-ff64y6ef | diagnostic, prognostic, predictive, and treatment implications Altered states: selectively drugging the Hsp90 cancer chaperone Heat shock proteins promote cancer: it's a protection racket Heat shock proteins and cancer: intracellular chaperones or extracellular signalling ligands? |
| cord-327135-4c2flue4 | : do interferon lambda 3 polymorphisms predict the outcome of interferon- therapy in hepatitis B infection? |
| cord-327135-4c2flue4 | One more piece in the interleukin 28B gene puzzle? |
| cord-327135-4c2flue4 | So the question arises: is the IFN- λ4-generating SNP the sole functional SNP or the other SNPs regulating the expression of IFN- λ3 also have independent roles? |
| cord-327135-4c2flue4 | So, how does the expression of a functional IFN- λ4 in patients who get an acute HCV infection will lead them to become chronically infected? |
| cord-265005-e6rpryrh | How type I interferons work in multiple sclerosis and other diseases: some unexpected mechanisms Role of type I interferons in inflammasome activation, cell death, and disease during microbial infection Does Type I interferon limit protective neutrophil responses during pulmonary Francisella Tularensis infection? |
| cord-265005-e6rpryrh | I IFN receptor- triggering of T cells and of DC is required to promote maximal modified vaccinia virus Ankara- induced T- cell expansion Antiviral immune responses: triggers of or triggered by autoimmunity? |
| cord-265005-e6rpryrh | Is chronic plaque psoriasis triggered by microbiota in the skin? |
| cord-265005-e6rpryrh | Plasmacytoid dendritic cells suppress HIV-1 replication but contribute to HIV-1 induced immunopathogenesis in humanized mice Chronic hepatitis C: future treatment Host- targeting agents in the treatment of hepatitis C: a beginning and an end? |
| cord-265005-e6rpryrh | Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness Pathology of human influenza revisited Immune dysfunction and bacterial coinfections following influenza Type I interferon: friend or foe? |
| cord-265005-e6rpryrh | The pathology of influenza virus infections How do viral infections predispose patients to bacterial infections? |
| cord-302295-nblmshni | Approaching the asymptote? |
| cord-302295-nblmshni | How important are Toll- like receptors for antimicrobial responses? |
| cord-302295-nblmshni | Sepsis studies need new direction Recombinant human activated protein C as a therapy for severe sepsis: lessons learned? |
| cord-302295-nblmshni | So, how to explore more efficiently new treatment strategies? |
| cord-302295-nblmshni | Targeting Toll- like receptors: emerging therapeutics? |
| cord-302295-nblmshni | The search for effective therapy for sepsis: back to the drawing board? |
| cord-344084-z4t2wkgk | , the following question arose: does CCR5 have any clinically relevant influence on SARS- CoV-2 or other coronaviruses infections? |
| cord-344084-z4t2wkgk | : forgotten or ignored? |
| cord-344084-z4t2wkgk | An emerging interplay between extracellular vesicles and cytokines Lack of chemokine receptor CCR5 promotes murine fulminant liver failure by preventing the apoptosis of activated CD1d- restricted NKT cells CCR5 in T cell- mediated liver diseases: what's going on? |
| cord-344084-z4t2wkgk | CCR5 polymorphism as a protective factor for hepatocellular carcinoma in hepatitis B virus- infected Iranian patients CD4-CCR5 interaction in intracellular compartments contributes to receptor expression at the cell surface Effects of the CCR5-Δ32 mutation on antiviral treatment in chronic hepatitis C Effects of the CCR5-Δ32 mutation on hepatitis C virus- specific immune responses in patients with haemophilia CC- chemokine receptor 5( CCR5) in hepatitis C-- at the crossroads of the antiviral immune response? |
| cord-344084-z4t2wkgk | Cells Chemokine receptors as important regulators of pathogenesis during arboviral encephalitis Enhanced expression, native purification, and characterization of CCR5, a principal HIV-1 coreceptor Dengue haemorrhagic fever: a job done via exosomes? |
| cord-022888-dnsdg04n | /CRTAM on gd T cells? |
| cord-022888-dnsdg04n | As the results show, could there not be a direct relationship between the HLA system and the development of SA or TBC, or in contrast, was the first patient missdiagnosed of TBC being a good prognosis SA? |
| cord-022888-dnsdg04n | Could Carabin play a role of negative regulator of B cell function? |
| cord-022888-dnsdg04n | How is the IGSF4-CRTAM axis regulated in T cells? |
| cord-022888-dnsdg04n | a one- year prospective birth cohort study PC09/16 TO WHAT EXTENT T- SPOT.TB COULD BE USED IN THE DIAGNOSIS OF TUBERCULOSIS IN CHILDREN EXPOSED TO TB INFECTION? |
| cord-009567-osstpum6 | ( for women) and"How difficult is it for you to get or keep an erection?" |
| cord-009567-osstpum6 | : Can We Afford It? |
| cord-009567-osstpum6 | :"How difficult is it for your vagina to get or stay wet or moist?" |
| cord-009567-osstpum6 | Roberto Hernandez- Alejandro, 1 Xusheng Zhang, 2 Dong Chen, 2 Xiufen Zheng, 2 Hongtao Sun, 2 Weihua Liu, 2 Marianne Beduhn, 2 Aminah Shunnar, 2 Motohiko Suzuki, 2 Norihiko Kubo, 2 Bertha Garcia, 2 Anthony Jevnikar, 1,2 Living kidney donation is rapidly increasing worldwide to offer a partial(?) solution for the numerous ESRD wait- listed pts. |
| cord-009567-osstpum6 | These include the phosphorylation of PERK target eIF2? |
| cord-009567-osstpum6 | or Not Enough? |
| cord-256118-gxhhwqdd | , see how the world is round? |
| cord-256118-gxhhwqdd | How much do you have, I would ask? |
| cord-256118-gxhhwqdd | The effects of the War on Drugs on people who inject drugs( PWID) in rural Puerto Rico Hepatitis C serosorting among people who inject drugs in rural Puerto Rico Injection- related Hepatitis C serosorting behaviors among people who inject drugs: an urban/ rural comparison Hepatitis C virus serosorting in people who inject drugs: sorting out the details Stories of pain and the problem of AIDS prevention: Injection drug withdrawal and its effects on risk behavior Beyond prevention? |
| cord-256118-gxhhwqdd | The process of drug injection: applying ethnography to the study of HIV risk among IDUs Commentary on Harris& Rhodes: discouraging syringe re- use by addressing drug injectors'everyday suffering Puerto rican syndemics: opiates, overdoses, HIV, and the hepatitis C virus in a context of ongoing crisis To enroll or not to enroll? |
| cord-256118-gxhhwqdd | The promise of treatment as prevention for hepatitis C: Meeting the needs of people who inject drugs? |
| cord-256118-gxhhwqdd | a systematic and methodological review Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus( HCV) infection using cross- sectional survey data Sharing cookers and cottons are surrogates for drug sharing Drug sharing among heroin networks: implications for HIV and hepatitis B and C prevention Social capital or networks, negotiations, and norms? |
| cord-256118-gxhhwqdd | gold Open Access which fosters wider collaboration and increased citations maximum visibility for your research: over 100 M website views per year submit your research? |
| cord-256118-gxhhwqdd | hepatitis C Do practice approaches go far enough in shifting focus from the individual? |
| cord-305085-bv7udg9k | : prospective cohort study from Durban Are HIVinfected women who breastfeed at increased risk of mortality? |
| cord-305085-bv7udg9k | A further report on cancer of the breast Repeated congenital infection with Toxoplasma gondii Is ingestion of milk associated bacteria by premature infants fed raw human milk controlled by routine bacteriologic screening? |
| cord-305085-bv7udg9k | Does breast feeding increase the child's risk of breast cancer? |
| cord-305085-bv7udg9k | HIV Infection in Newborns French Collaborative Study Group Clinical Virology Postpartum varicella vaccination: Is the vaccine virus excreted in breast milk? |
| cord-305085-bv7udg9k | How well will they work were they are needed most? |
| cord-305085-bv7udg9k | Ing et al 194 investigated the question,"Does the unsuckled breast have an altered risk for cancer? |
| cord-305085-bv7udg9k | Is breast milk collected at home suitable for raw consumption by neonates in Brizilian public neonatal intensive care units? |
| cord-305085-bv7udg9k | Morbidity in children born to women infected with human immunodeficiency virus in South Africa: Does mode of feeding matter? |
| cord-305085-bv7udg9k | Neonatal group B streptococcal infection related to breast milk Epidemiology of tuberculosis in the United States Probable transmission of brucellosis by breast milk Does discarding the first few milliliters of breast milk improve the bacteriological quality of bank breast milk? |
| cord-305085-bv7udg9k | New frontiers in an old dilemma Breastfeeding and the risk of life- threatening rotavirus diarrhea: Prevention or postponement? |
| cord-305085-bv7udg9k | Revised guidelines from CDC Detection of TT virus DNA and GB virus type C/ hepatitis G virus RNA in serum and breast milk: Determination of mother- to- child transmission Effects of hepatitis A and B in pregnancy on the mother and fetus Human immunodeficiency virus load in breast milk, mastitis and mother- to- child transmission of human immunodeficiency virus type 1 How contagious is vaccinia? |
| cord-305085-bv7udg9k | The yeast connection: is Candida linked to breastfeeding associated pain? |
| cord-305085-bv7udg9k | Which measures for which success? |
| cord-305085-bv7udg9k | Who should receive rifampin? |
| cord-000083-3p81yr4n | Between patients with HOMA- IR positive and negative, however, statistically no significant difference was found in terms of age, sex, etiology, Child- Pugh classification, spleen size, TNF-?, |
| cord-000083-3p81yr4n | Do we all failed in addressing socio- economic issues of cancer- sufferers? |
| cord-000083-3p81yr4n | IL-1? |
| cord-000083-3p81yr4n | IL-1? |
| cord-000083-3p81yr4n | IL-1? |
| cord-000083-3p81yr4n | IL-1? |
| cord-000083-3p81yr4n | In additon, we aimed to investigate the relation of insulin resistance in liver cirrhosis with such parameters as age, sex, etiology, Child- Pugh classification, spleen size, TNF-?, IL-1? |
| cord-000083-3p81yr4n | In additon, we aimed to investigate the relation of insulin resistance in liver cirrhosis with such parameters as age, sex, etiology, Child- Pugh classification, spleen size, TNF-?, IL-1? |
| cord-000083-3p81yr4n | In liver cirrhosis group, glucose, insulin, C- peptid, HOMA- IR, TNF-? |
| cord-000083-3p81yr4n | In patients with liver cirrhosis, the levels of glucose, insulin, C- peptid, HOMA- IR, TNF-?, IL-2RES, IL-6, CRP and Hs- CRP increase with respect to normal population. |
| cord-000083-3p81yr4n | In the study, it was also determined that the mechanism of insulin resistance development occurs independent of age, sex, etiology, Child- Pugh classification, spleen size, TNF-?, |
| cord-000083-3p81yr4n | The two groups were compared with each other in terms of glucose, insulin, C- peptid, HOMA- IR, TNF-?, |
| cord-000083-3p81yr4n | These two groups, i.e., HOMA- IR positive and HOMA- IR negative, were compared in terms of age, sex, etiology, Child- Pugh classification, spleen size, TNF-?, |
| cord-010088-s9tfvtao | 3C- S14- 01 DO WE REALLY NEED FFP? |
| cord-010088-s9tfvtao | But is this a myth? |
| cord-010088-s9tfvtao | But was the three- gene theory really wrong, when the boundaries of genes were not understood at the time? |
| cord-010088-s9tfvtao | But who decides what is false? |
| cord-010088-s9tfvtao | How can they be investigated and what should be considered? |
| cord-010088-s9tfvtao | How do I know if I have enough information to write a paper? |
| cord-010088-s9tfvtao | How has this happened? |
| cord-010088-s9tfvtao | How should my paper be put together to give it the best chance of being accepted? |
| cord-010088-s9tfvtao | If it is returned to me with comments from the reviewers, what should I do? |
| cord-010088-s9tfvtao | Is it an ATMP or non- manipulated cell product, is it a blood product or a pharmaceutical? |
| cord-010088-s9tfvtao | NEXT? |
| cord-010088-s9tfvtao | WHATS NEW WITH TRALI? |
| cord-010088-s9tfvtao | What happens to my paper after I submit it? |
| cord-010088-s9tfvtao | What is my next step if my paper is rejected, either without review or with review? |
| cord-010088-s9tfvtao | What is the value of discussing case studies? |
| cord-010088-s9tfvtao | What should be considered in different clinical situations? |
| cord-010088-s9tfvtao | Where should I try to publish the paper? |
| cord-318853-mxyxwkhx | 5 5'UTR geq/ ml at 16 weeks be visible immunologically, but envelope proteins derived from EeRNA sequences corresponding to~10 6- 7 5'UTR geq/ ml at 4- 6 weeks remain unseen? |
| cord-318853-mxyxwkhx | Analysis of cloned DNA gives cleaner data than PCR sequencing but if 100 clones( and multiple HCV quasispecies clones are highly unlikely to be identical) provides definitive sequence, would we process the 101 st to reveal different and, potentially, critical sequence variations? |
| cord-318853-mxyxwkhx | And if we did, how would we recognise its importance? |
| cord-318853-mxyxwkhx | As clear evidence exists for viral disruption of leptin function[ 106] and virus- associated weight gain in humans[ 107] and monkeys[ 108], is it possible the global epidemics of type II diabetes mellitus, insulin resistance, hyperlipidaemia and obesity now prevalent[ 109][ 110][ 111][ 112][ 113][ 114][ 115][ 116], are just that; epidemics fundamentally caused by viruses that co- opt insulin or leptin or other associated receptors for cell access and generate protein quasispecies that disrupt receptor function? |
| cord-318853-mxyxwkhx | But does this certitude reflect reality, at least for viral RNA quasispecies? |
| cord-318853-mxyxwkhx | But why should specific EeRNA sequence frequencies-in other words, HCV RNA pol fidelity-increase after week 8, facilitating adaptive immune responses? |
| cord-318853-mxyxwkhx | Could it also be that ethnically based epidemics of obesity, diabetes mellitus, hypertension and reno- vascular disease( the'metabolic syndrome'), as seen in PIMA Indians, Nauruans and Australian Aborigines[ 115] have developed not primarily because of exposure to"Western"foods and lifestyles-that, after all, are all- pervasive without necessarily having so dramatic an effect on other groups-but because of chronic or recurrent exposure to viruses, or genotypes of viruses to which their particular repertoire of receptor polymorphisms confer no protection? |
| cord-318853-mxyxwkhx | Finally, if immune mechanisms are unable to clear RNA viruses like HCV and do not cause the reduced viral replication seen during acute infection, are they any more likely to be effective against other RNA viruses? |
| cord-318853-mxyxwkhx | I receptor signaling system in JC virus T antigen- induced primitive neuroectodermal tumors-medulloblastomas Hepatitis C virus down- regulates insulin receptor substrates 1 and 2 through up- regulation of suppressor of cytokine signaling 3 Vaccinia virus and the EGF receptor: a portal for infectivity? |
| cord-318853-mxyxwkhx | Is important sequence likely to be present at frequencies of http://www.virologyj.com/content/2/1/70< 1%? |
| cord-318853-mxyxwkhx | Is it possible foetal tolerance is mediated by regulating the fidelity of foetal DNA dependent RNA transcriptases to ensure any cell- surface antigens are expressed heterogeneously and at levels below the threshold of maternal immune responsiveness? |
| cord-318853-mxyxwkhx | Is it possible that self- limiting infections like influenza and SARS also autoregulate their replication, and, like HCV or HBV, become partially dormant, yet remain transcriptionally active, in the face of an active and powerful immune response? |
| cord-318853-mxyxwkhx | The expected consequences disruption of receptor function by variant viral proteins might explain many common biochemical pathologies; For example, what effect would chronic blockade of parathyroid( PTH) receptors by viral proteins have on PTH levels, the parathyroid glands, or bone? |
| cord-318853-mxyxwkhx | This is certainly an accurate synthesis of an extensive and highly complex literature but does it make any sense? |
| cord-318853-mxyxwkhx | What practical meaning does"immune control"have for the individual? |
| cord-318853-mxyxwkhx | Why should HCV replicating at 10 6- 7 geq/ ml at week 6 be invisible to the immune system but visible when replicating at 10 5 geq/ ml long term? |
| cord-023017-k6edtg58 | ( I? |
| cord-023017-k6edtg58 | 12mmHg or by? |
| cord-023017-k6edtg58 | 12mmHg or? lo%), had a significantly lower probability of bleeding( P?O.Ol) and of requiring hospital admission because decompensations of cirrhosis, while survival probability was higher, both after acute and chronic beta- blocker administration. |
| cord-023017-k6edtg58 | 2) what are the risk factors of IR; 3) does IR play a role( and to what extent) in the occurrence of steatosis? |
| cord-023017-k6edtg58 | 20% in 38% of cases and decreased? lo% in 74%( P?O.OOl) after acute beta- blocker. |
| cord-023017-k6edtg58 | 4) is IR involved in the progression of fibrosis? |
| cord-023017-k6edtg58 | Control( 0.65 cellsltriad? |
| cord-023017-k6edtg58 | Hemodynamic responders( defining response as a decrease of HVPG to? |
| cord-023017-k6edtg58 | If CD34 numbers are adjusted for the total mononuclear cell counts then the increase in circulating stem cells between these two groups became even more apparent( 0.44? 0.34 and 4.98XlOX6 cellsll 24.8; p<0.05). |
| cord-023017-k6edtg58 | In patients with chronic hepatitis C, we adressed the following issues: 1) is IR the cause or consequence of steatosis and fibrosis? |
| cord-023017-k6edtg58 | Methods: Chronic liver injury was induced in rats by CC14 treatment( of the development of cirrhosis in Group 1( histopathology score of 3.7? |
| cord-023017-k6edtg58 | Our results suggest that: 1) A decrease of HVFG? |
| cord-023017-k6edtg58 | Overall, patients with PNF were older( 55.7 t 10 vs. 48.99 years, p=0.03) and had higher peak ALT levels( 141? 185 vs. 40 2 32 U/ L, p=0.04). |
| cord-023017-k6edtg58 | Studies dealing with the prevention of rebleeding have shown that hemodynamic response to pharmacological treatment of portal hypertension is adequate when the hepatic venous pressure gradient( HVPG) decreases to? |
| cord-023017-k6edtg58 | The HCV RNA was done by a PCR technique with a detectability cutoff of 50-copieslmb Results: Both randomized groups were similar at baseline without statistical significant difference, 190( 90%) were infected with genotype 4, mean age was 39.5 years? |
| cord-023017-k6edtg58 | The HVPG decreased? |
| cord-023017-k6edtg58 | The area of ASMA- positive cells was however significantly decreased by SSR 182289 from 3.83? 1.04 to 2.86 |
| cord-023017-k6edtg58 | The mean level of circulating apoptotic cells in Day 1 recipient PBMC was higher than healthy controls( 0.9% t-0.2 vs 0.2%? |
| cord-023017-k6edtg58 | Using ROC curve a decrease of HVPG? |
| cord-350571-6tapkjb6 | DI012: Wikipedia and medicines: who edits medicine articles on the English Wikipedia? |
| cord-350571-6tapkjb6 | Does a hospital formulary system impact timely medication administration and quality of inpatient care? |
| cord-350571-6tapkjb6 | From those who were treated by TMP/ SMX, following data were collected: age, gender, weight, doses, and indications( probabilistic? documented? |
| cord-350571-6tapkjb6 | From those who were treated by TMP/ SMX, following data were collected: age, gender, weight, doses, and indications( probabilistic? documented? |
| cord-350571-6tapkjb6 | From those who were treated by carbapenems, PIP/ TAZ or AMX AC, following data were collected: age, gender, weight, doses, indications( probabilistic? documented? |
| cord-350571-6tapkjb6 | From those who were treated by carbapenems, PIP/ TAZ or AMX AC, following data were collected: age, gender, weight, doses, indications( probabilistic? documented? |
| cord-350571-6tapkjb6 | HP- PC015: Discharged patients: a problem for community pharmacists? |
| cord-350571-6tapkjb6 | HP- PC027: QT- prolongation in an acute psychiatric setting: fact or fiction? |
| cord-350571-6tapkjb6 | HP- PC068: Are hospital pharmaceutical staff educated on the criticality of thermosensitive drugs? |
| cord-350571-6tapkjb6 | HP- PC134: How the centralization of medicines manufacturing enable to generalize the pharmaceutical validation? |
| cord-350571-6tapkjb6 | Mapping of the DLQI scores to EQ-5D utility values using ordinal logistic regression and Monte Carlo simulations: is it plausible? |
| cord-350571-6tapkjb6 | On the question''What is your general perception of the benefit of the clinical pharmacy service; for collaborating health professionals? |
| cord-350571-6tapkjb6 | Personal changes in drug regimen: dangerous for health system? |
| cord-350571-6tapkjb6 | The office of access to healthcare: how to optimize secured access to treatments? |
| cord-350571-6tapkjb6 | The open questions:''What disadvantages/ advantages have you experienced by the introduction of clinical pharmacist into multidisciplinary teams?''received 153/185 comments respectively. |
| cord-350571-6tapkjb6 | The research questions were: When comparing dicloxacillin with other antibiotics commonly used in children,( 1) is there a difference in the age of conversion from liquid to solid formulation and( 2) is there a difference in re- prescription rates on day 1 and 2 after the initial prescription? |
| cord-350571-6tapkjb6 | for the patient?''the total benefit was ranked 5.45 and 5.54 respectively( Scale from 0(''no benefit'') to 6(''beneficial to a very large extent''). |
| cord-010092-uftc8inx | Can you confirm my genotype? cord-010092-uftc8inx Who is a blood donor recruiter?"was the topic of ABD- VII at 9- 11 March 2018. |
| cord-010092-uftc8inx | 4A- S18- 05 WHO IS SYPHILIS TESTING EXCLUDING? |
| cord-010092-uftc8inx | : IS IT TIME TO LABEL EACH UNIT WITH HB CONTENT? |
| cord-010092-uftc8inx | A donor was classified as"tired"if they responded"all the time"or"most of the time"to the question"how often do you feel that you lacked energy and strength?". |
| cord-010092-uftc8inx | ALL TOGETHER? |
| cord-010092-uftc8inx | Are we alone in the Universe? |
| cord-010092-uftc8inx | As a consequence, questions asked 30 years ago have changed: Today, molecular biologists looking at hundreds of newly discovered blood group alleles find themselves not being asked by serologists any more:"Can you confirm my serology?", but instead, pose their question to the experts for the blood group phenotype: |
| cord-010092-uftc8inx | But can we apply the metaphor as successfully into donating blood for research? |
| cord-010092-uftc8inx | Donors and Donation-Donor Adherence-are we doing the Right Thing? |
| cord-010092-uftc8inx | How can we start using this tool in unison with our existing tools to improve science and clinical practice in our respective( bio)medical fields? |
| cord-010092-uftc8inx | So is there a future for new anti- platelet agents? |
| cord-010092-uftc8inx | To evaluate self- rated health we used the well- validated single question:"How would you rate your health in general?". |
| cord-010092-uftc8inx | WHAT CAN WE LEARN FROM HOW ADVERSE EVENTS ARE DETECTED? |
| cord-010092-uftc8inx | What is the optimal balance between iron supplementation and prolongation of interdonation intervals? |
| cord-010092-uftc8inx | What then is the best approach to use? |
| cord-010092-uftc8inx | Where are we from? |
| cord-010092-uftc8inx | Where are we going? |
| cord-010092-uftc8inx | Will serologic typing be replaced by DNAbased typing? |
| cord-010092-uftc8inx | but how does this affect health? |
| cord-010119-t1x9gknd | Among all potential causes investigated, only the gel card lot number was associated with the number of"?"generated( table 1). |
| cord-010119-t1x9gknd | Assuming 30 seconds of technologist time per"?", we estimate that 13.6 hours were needed to resolve and update these results. |
| cord-010119-t1x9gknd | Can Texting Decrease Wastage? |
| cord-010119-t1x9gknd | Interference: More Than Just Kell? |
| cord-010119-t1x9gknd | Is Its Use Inappropriate? |
| cord-010119-t1x9gknd | Of 19,647 columns run as part of antibody screens, 1,633( 8.3%) columns generated"? |
| cord-010119-t1x9gknd | Patient 1 was a 29 yo female, C2E2c1e1, whose RBCs reacted 11 by ECHO and 31 by NEO with anti- D4, and'?' |
| cord-010119-t1x9gknd | Platelet Rich Plasma and Quality Control: Is There a Role for the Blood Bank? |
| cord-010119-t1x9gknd | Shortly after implementation, technologists reported increased time spent performing manual resolution of indeterminate( designated as"?") results. |
| cord-010119-t1x9gknd | Study Design/ Method: We analyzed allogeneic interview responses to the screening question,"In the past 12 months have you had a tattoo?" |
| cord-010119-t1x9gknd | Study Design/ Methods: With assistance from Ortho Diagnostics, analyzer archives were queried to identify the number of gel card columns used for screens, the number of columns with"?"results, and the gel card lot numbers used for testing from 1/29/2017 to 3/31/2017. |
| cord-010119-t1x9gknd | Testing Worth the Headache? |
| cord-010119-t1x9gknd | Texas Children's Hospital, 2 Baylor College of Medicine AP127 Vision Titers--Easier or Problematic? |
| cord-010119-t1x9gknd | The Future of Plasma Therapy? |
| cord-010119-t1x9gknd | The incidence of"?"and visually negative analyzer positive results is dependent on the specific lot of MTS- Gel TM cards used. |
| cord-010119-t1x9gknd | The objective of this study was to investigate the cause of"?"and apparent false positive results on VisionV R three- cell antibody screens. |
| cord-010119-t1x9gknd | Variations in Biochemical Markers of Bone Metabolism during Plateletpheresis: Impact of Socio- Demographic and Lifestyle Factors? |
| cord-010119-t1x9gknd | Were Patients Transfused after Testing? |
| cord-010119-t1x9gknd | What Is the Best Practice for Testing Residual White Blood Cells in Blood Components for Monthly Routine Quality Control? |
| cord-010119-t1x9gknd | Where We Go? |
| cord-007890-bie1veti | ( 5?-GCAAGTTCTT- CAGCTTGTTT-3?). |
| cord-007890-bie1veti | ( 5?-TATTGCGCT- TAGAAAATTAA-3?) |
| cord-007890-bie1veti | ( hence, if we treat alcoholic cirrhosis patients with interferon could we have a favorable response?). |
| cord-007890-bie1veti | */does its aetiology matter? |
| cord-007890-bie1veti | And on the basis of which classification system should the two legs of such a trial be separated? |
| cord-007890-bie1veti | Can coins and paper currency transmit Bacillus anthracis? |
| cord-007890-bie1veti | Can varicella be eliminated by universal childhood vaccination? |
| cord-007890-bie1veti | Do the trials with interferon alfa for patients with HBV or HCV cirrhosis exhibit a favorable result due to the antiviral properties of interferon, or is interferon exhibiting anti- oncogenic potential?, and is HCC cytokine and hormone sensitive( view ongoing trials with somatostatine analogues versus HCC)? |
| cord-007890-bie1veti | Do the trials with interferon alfa for patients with HBV or HCV cirrhosis exhibit a favorable result due to the antiviral properties of interferon, or is interferon exhibiting anti- oncogenic potential?, and is HCC cytokine and hormone sensitive( view ongoing trials with somatostatine analogues versus HCC)? |
| cord-007890-bie1veti | Does their end in the stage of cirrhosis? |
| cord-007890-bie1veti | HBV Á/ HCV and liver carcinogenesis: where does the viral influence end? |
| cord-007890-bie1veti | How ethical is it to conduct a randomised trial where one leg of cirrhotic patients is left without antiviral therapy? |
| cord-007890-bie1veti | How much hope can be put on a drug that seems to be partly useless before its initiation? |
| cord-007890-bie1veti | In vivo activity of glycopeptides against S. aureus infection in a rabbit endocarditis model: is MIC predictive for in vivo efficacy? |
| cord-007890-bie1veti | Is progression towards HCC independent of the etiology of cirrhosis( since alcoholic cirrhosis also proceeds to HCC)? |
| cord-007890-bie1veti | Lactulose, a factor that decreases endotoxaemia, in obstructive jaundice? |
| cord-007890-bie1veti | Moreover, do viral proteins with oncogenic potential exist( the controversy over the recently discovered HBV protein is still, unresolved)? |
| cord-007890-bie1veti | Our experience suggests a promising role of lamivudine in the treatment of acute hepatitis B, but how long such therapy have to be practiced and in which patients? |
| cord-007890-bie1veti | These strains was genotypically characterized for the mec A gene presence by PCR method using the mec A 1- 5?-AAA ATC CAT GGT AAA GGT TGG C-3? and the mec A 2 Á/5?-AGT TCT GCA GTA CCG GAT TTG C-3? primers( GIBCO, BRL). |
| cord-007890-bie1veti | These strains was genotypically characterized for the mec A gene presence by PCR method using the mec A 1- 5?-AAA ATC CAT GGT AAA GGT TGG C-3? and the mec A 2 Á/5?-AGT TCT GCA GTA CCG GAT TTG C-3? primers( GIBCO, BRL). |
| cord-007890-bie1veti | Which patients with HBV or HCV cirrhosis are eligible for interferon treatment? |
| cord-007890-bie1veti | and of transconjugants and the amplification by PCR of the gene aac(6?)-aph(2?? |
| cord-007890-bie1veti | and of transconjugants and the amplification by PCR of the gene aac(6?)-aph(2?? |
| cord-007890-bie1veti | can the associated morbidity and mortality in this rare but deadly disease be reduced? |
| cord-023364-ut56gczm | ( with a selfadministered questionnaire with an open- ended question: How does blood donation affect you? |
| cord-023364-ut56gczm | /socially during or after blood donation?) revealed that perceived negative effects( fatigue, diminished physical working capacity, vertigo/ dizziness, susceptibility to infections etc) |
| cord-023364-ut56gczm | : will it become reality? |
| cord-023364-ut56gczm | After the first 10 years with haemovigilance in the European countries, what has been the outcome of this big effort? |
| cord-023364-ut56gczm | Against this background where should our attentions focus? |
| cord-023364-ut56gczm | Aim: Does the interpretation of reports obtained through Outcome Review lead to an increase in the number of products per run and the overall productivity of the apheresis center? |
| cord-023364-ut56gczm | An ISO standard for blood transfusion? |
| cord-023364-ut56gczm | Are transfusion guidelines evidence- based? |
| cord-023364-ut56gczm | Being anti- D immunoglobulin a product that has the potential risk of infection transmission, is it appropriate to use indiscriminately as a routine antenatal prophylaxis? |
| cord-023364-ut56gczm | In addition, how much are we willing to pay for protection against emerging viruses? |
| cord-023364-ut56gczm | Is it a mutual decision making between physician and patient? |
| cord-023364-ut56gczm | Mobilization is also seen following the use of other cytokines( i.e. kit- L, Flt-3 L, IL-3) or chemokines( i.e. IL-8, Gro?), complement activation, etc., but the detailed mechanisms or the interdependence of these other pathways with the ones already proposed have not been worked out. |
| cord-023364-ut56gczm | Scientific evidence to fully answer the questions'when are platelet components clinically effective'and'what do we really know?'is limited. |
| cord-023364-ut56gczm | Should patients with thalassemia intermedia be regularly transfused? |
| cord-023364-ut56gczm | The research theme of this questionnaire is as follows:'What is the level of knowledge and of motivation in the non- remunerated and voluntary blood donation at students?' |
| cord-023364-ut56gczm | The subjects selected and debated were( i) what are the medical considerations for reducing the rate of mistransfusion? |
| cord-023364-ut56gczm | These ties to industry create a tension that actually is or can be perceived as • work internationally; • send young volunteers to international youth forums; • employ young people in your organisation; Why use volunteers in blood donor recruitment? |
| cord-023364-ut56gczm | We therefore resorted to developing our own model but ask the question: Why not have one international standard for blood transfusion? |
| cord-023364-ut56gczm | What is however the meaning of informed consent? |
| cord-023364-ut56gczm | Who cares about the quality of life of the chronic patients treated with blood products? |
| cord-023364-ut56gczm | Who will hear it? |
| cord-023364-ut56gczm | and( ii) what are the medical considerations for managing a limited blood inventory? |
| cord-023364-ut56gczm | to apply which screening method? |
| cord-023364-ut56gczm | your Trima ® can be? |
| cord-023354-f2ciho6o | ( with a selfadministered questionnaire with an open- ended question: How does blood donation affect you? |
| cord-023354-f2ciho6o | /socially during or after blood donation?) revealed that perceived negative effects( fatigue, diminished physical working capacity, vertigo/ dizziness, susceptibility to infections etc) |
| cord-023354-f2ciho6o | : will it become reality? |
| cord-023354-f2ciho6o | After the first 10 years with haemovigilance in the European countries, what has been the outcome of this big effort? |
| cord-023354-f2ciho6o | Against this background where should our attentions focus? |
| cord-023354-f2ciho6o | Aim: Does the interpretation of reports obtained through Outcome Review lead to an increase in the number of products per run and the overall productivity of the apheresis center? |
| cord-023354-f2ciho6o | An ISO standard for blood transfusion? |
| cord-023354-f2ciho6o | Are transfusion guidelines evidence- based? |
| cord-023354-f2ciho6o | Being anti- D immunoglobulin a product that has the potential risk of infection transmission, is it appropriate to use indiscriminately as a routine antenatal prophylaxis? |
| cord-023354-f2ciho6o | In addition, how much are we willing to pay for protection against emerging viruses? |
| cord-023354-f2ciho6o | Is it a mutual decision making between physician and patient? |
| cord-023354-f2ciho6o | Mobilization is also seen following the use of other cytokines( i.e. kit- L, Flt-3 L, IL-3) or chemokines( i.e. IL-8, Gro?), complement activation, etc., but the detailed mechanisms or the interdependence of these other pathways with the ones already proposed have not been worked out. |
| cord-023354-f2ciho6o | Scientific evidence to fully answer the questions'when are platelet components clinically effective'and'what do we really know?'is limited. |
| cord-023354-f2ciho6o | Should patients with thalassemia intermedia be regularly transfused? |
| cord-023354-f2ciho6o | The research theme of this questionnaire is as follows:'What is the level of knowledge and of motivation in the non- remunerated and voluntary blood donation at students?' |
| cord-023354-f2ciho6o | The subjects selected and debated were( i) what are the medical considerations for reducing the rate of mistransfusion? |
| cord-023354-f2ciho6o | These ties to industry create a tension that actually is or can be perceived as • work internationally; • send young volunteers to international youth forums; • employ young people in your organisation; Why use volunteers in blood donor recruitment? |
| cord-023354-f2ciho6o | We therefore resorted to developing our own model but ask the question: Why not have one international standard for blood transfusion? |
| cord-023354-f2ciho6o | What is however the meaning of informed consent? |
| cord-023354-f2ciho6o | Who cares about the quality of life of the chronic patients treated with blood products? |
| cord-023354-f2ciho6o | Who will hear it? |
| cord-023354-f2ciho6o | and( ii) what are the medical considerations for managing a limited blood inventory? |
| cord-023354-f2ciho6o | to apply which screening method? |
| cord-023354-f2ciho6o | your Trima ® can be? |
| cord-023346-8sqbqjm1 | ( with a selfadministered questionnaire with an open- ended question: How does blood donation affect you? |
| cord-023346-8sqbqjm1 | /socially during or after blood donation?) revealed that perceived negative effects( fatigue, diminished physical working capacity, vertigo/ dizziness, susceptibility to infections etc) |
| cord-023346-8sqbqjm1 | : will it become reality? |
| cord-023346-8sqbqjm1 | After the first 10 years with haemovigilance in the European countries, what has been the outcome of this big effort? |
| cord-023346-8sqbqjm1 | Against this background where should our attentions focus? |
| cord-023346-8sqbqjm1 | Aim: Does the interpretation of reports obtained through Outcome Review lead to an increase in the number of products per run and the overall productivity of the apheresis center? |
| cord-023346-8sqbqjm1 | An ISO standard for blood transfusion? |
| cord-023346-8sqbqjm1 | Are transfusion guidelines evidence- based? |
| cord-023346-8sqbqjm1 | Being anti- D immunoglobulin a product that has the potential risk of infection transmission, is it appropriate to use indiscriminately as a routine antenatal prophylaxis? |
| cord-023346-8sqbqjm1 | In addition, how much are we willing to pay for protection against emerging viruses? |
| cord-023346-8sqbqjm1 | Is it a mutual decision making between physician and patient? |
| cord-023346-8sqbqjm1 | Mobilization is also seen following the use of other cytokines( i.e. kit- L, Flt-3 L, IL-3) or chemokines( i.e. IL-8, Gro?), complement activation, etc., but the detailed mechanisms or the interdependence of these other pathways with the ones already proposed have not been worked out. |
| cord-023346-8sqbqjm1 | Scientific evidence to fully answer the questions'when are platelet components clinically effective'and'what do we really know?'is limited. |
| cord-023346-8sqbqjm1 | Should patients with thalassemia intermedia be regularly transfused? |
| cord-023346-8sqbqjm1 | The research theme of this questionnaire is as follows:'What is the level of knowledge and of motivation in the non- remunerated and voluntary blood donation at students?' |
| cord-023346-8sqbqjm1 | The subjects selected and debated were( i) what are the medical considerations for reducing the rate of mistransfusion? |
| cord-023346-8sqbqjm1 | These ties to industry create a tension that actually is or can be perceived as • work internationally; • send young volunteers to international youth forums; • employ young people in your organisation; Why use volunteers in blood donor recruitment? |
| cord-023346-8sqbqjm1 | We therefore resorted to developing our own model but ask the question: Why not have one international standard for blood transfusion? |
| cord-023346-8sqbqjm1 | What is however the meaning of informed consent? |
| cord-023346-8sqbqjm1 | Who cares about the quality of life of the chronic patients treated with blood products? |
| cord-023346-8sqbqjm1 | Who will hear it? |
| cord-023346-8sqbqjm1 | and( ii) what are the medical considerations for managing a limited blood inventory? |
| cord-023346-8sqbqjm1 | to apply which screening method? |
| cord-023346-8sqbqjm1 | your Trima ® can be? |
| cord-002774-tpqsjjet | ( 2) does participation in drug treatment programs increase social capital?, and( 3) is there a significant difference among treatment modalities in affecting change in~ial capital? |
| cord-002774-tpqsjjet | ( 2) does participation in drug treatment programs increase social capital?, and( 3) is there a significant difference among treatment modalities in affecting change in~ial capital? |
| cord-002774-tpqsjjet | Die: How to Save our Children? |
| cord-002774-tpqsjjet | Findings suggest that HM have less access t? |
| cord-002774-tpqsjjet | How can we Measure this Elusive Goal? |
| cord-002774-tpqsjjet | How do AIDS mortality and fatality rates vary when related community characteristics, such as household income, ethnic mix, and geographic access to primary and ancillary HIV/ AIDS services are considered? |
| cord-002774-tpqsjjet | How has the widespread availability of HAART( after 1996) impacted AIDS outcomes at the community level? |
| cord-002774-tpqsjjet | However, as part of an ongoing study? |
| cord-002774-tpqsjjet | In June 2004, the Association of? |
| cord-002774-tpqsjjet | Moreover, there is n? basis for assessing the impact of the resultant initiatives to improve health~onditions amo~ g~o":1":1um ties settled in unplanned areas. |
| cord-002774-tpqsjjet | Nearly all participants( 97%) reported a history of contact with drug llt.lnnent services( methadone maintenance, rehabilitation clinics and judicial treatment), mental health car? |
| cord-002774-tpqsjjet | Since urban areas are more than the aggregation? |
| cord-002774-tpqsjjet | System for Homeless, HIV- infected Patients in NYC? |
| cord-002774-tpqsjjet | The increase m parnc1pat10n, the CHR mvolvement in the community, and the positive feedback from the agen? |
| cord-002774-tpqsjjet | The moot question in all the above observed development are: has the city rationally addressed it planning needs? |
| cord-002774-tpqsjjet | The principle research questions were: 1) What is the relationship between the locations of areas with concentrations of PL WA and the distribution of both primary and ancillary service providers? |
| cord-002774-tpqsjjet | The quesuon to be explore.cl 1~: If health care is available and accessible to one person, what makes it not available to all people? |
| cord-002774-tpqsjjet | The research questions were: What are the effects of homelessness on health? |
| cord-002774-tpqsjjet | Two research questions were investigated: are there spatial patterns to the events dis · tribution, and moreover, are these patterns overlapping across space? |
| cord-002774-tpqsjjet | What kind of supports are needed for homeless people to get off the street? |
| cord-002774-tpqsjjet | When the govern · ment withdrew from direct service provision as reform trends and donor advocacy suggested, how does it perform its new indirect role of managing relations with new direct health services providers in terms of regulating, enabling, and managing relations with these health services providers? |
| cord-002774-tpqsjjet | When/(calen · dar time), By 2, fisher exact and t were appliedxwhom( authors?). |
| cord-002774-tpqsjjet | Who and Why? |
| cord-002774-tpqsjjet | Why children die in Bangladesh? |
| cord-002774-tpqsjjet | _ contacts these women via? |
| cord-002774-tpqsjjet | a report of the efforts being made towards such a goal: The paper descr~ bes~ c~ se study? |
| cord-002774-tpqsjjet | and dent~ I hygiene t? |
| cord-002774-tpqsjjet | blocks, we considered a broad range of factors including evidence of homogeneity an~ heterogeneity( socmeconomic, ethnic, housing type, environmental) across blocks within and blocks ad1acent to a nei.ghborhood, and across the 36 sample neighborhoods; the potential for efficient recruit · ment of appropriate particip.ants( i.e. sufficient local pedestrian traffic); and boundaries used in reporting census data( s? |
| cord-002774-tpqsjjet | cQue tenemos para aprender de las"soluciones"que ellos mismos encuenrran a los usos problemat1cos? |
| cord-002774-tpqsjjet | dema~~a? |
| cord-002774-tpqsjjet | en estas comunidades? |
| cord-002774-tpqsjjet | t) does social capital predict parti~ ipating in treatment programs? |
| cord-002774-tpqsjjet | to all pama~~g? |
| cord-002774-tpqsjjet | ~i~ an~ s were recruited from drop in centres in 7 cities across |
| cord-002774-tpqsjjet | ~ts: In addmon to reporting process data and descriptions of the SIF users, we report on data indicating that the establishment of the SIF has been independently associated with reductions in public~': ° g~( p |